Cavalier Investments’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Cavalier Investments’s Portfolio BSTC Stock Details BSTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-7,800	Closed	-$417K	–	155
2019 Q3	$417K	Hold	7,800	–	–	0.18%	91
2019 Q2	$466K	Hold	7,800	–	–	0.19%	82
2019 Q1	$486K	Buy	7,800 +3,100	+66%	+$205K	0.2%	95
2018 Q4	$285K	Buy	+4,700	New	+$281K	0.09%	134
2016 Q1	–	Sell	-4,700	Closed	-$202K	–	139
2015 Q4	$202K	Buy	+4,700	New	+$235K	0.12%	109

Other funds holding BSTC

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cavalier Investments's BSTC Position: Q4 2019 in Review

Cavalier Investments sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2019, closing a stake of 7,800 shares — an estimated $417K sold.

Cavalier Investments first reported a position in BSTC in Q4 2015 and held it in 5 quarters. The position peaked at $486K in Q1 2019. 112 funds tracked by Wall St. Rank hold BSTC as of Q4 2019.

Cavalier Investments reported no remaining BioSpecifics Technologies Corp. position as of Q4 2019 after selling out during the quarter.
Cavalier Investments sold 7,800 BioSpecifics Technologies Corp. shares in Q4 2019, an estimated $417K.
Cavalier Investments first reported a position in BioSpecifics Technologies Corp. in Q4 2015 and held it in 5 quarters.
Cavalier Investments's BioSpecifics Technologies Corp. position peaked at $486K in Q1 2019.
112 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2019.

Based on Cavalier Investments's 13F filing for Q4 2019, filed 6 Feb 2020.